Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Once-daily antidiabetic drug from Andrx steadily advances towards market launch

Jan. 11, 2000

Compounds for osteoporosis in development at Japanese lab

Jan. 11, 2000

Neurocrine Biosciences licenses antidiabetic compound to Taisho

Jan. 11, 2000

Unigene files IND for nasal calcitonin

Jan. 11, 2000

Cangene revamps Leucotropin clinical trial program

Jan. 11, 2000

Tibolone plus long-term GnRH agonist evaluated in uterine leiomyoma therapy

Jan. 11, 2000

Sumitomo to develop BDNF for new indication: diabetes

Jan. 10, 2000

Agents for improving insulin resistance designed by AHP scientists

Jan. 10, 2000

Glaxo discovers PPARgamma agonist with excellent pharmacological and pharmacokinetic profile

Jan. 6, 2000

Protein-tyrosine-phosphatases explored at AHP as novel target for diabetes Rx

Jan. 6, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...